Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar po...

Full description

Saved in:
Bibliographic Details
Published inACS infectious diseases Vol. 6; no. 5; pp. 909 - 915
Main Authors Xu, Jimin, Shi, Pei-Yong, Li, Hongmin, Zhou, Jia
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 08.05.2020
Subjects
Antiviral Agents - pharmacology
Betacoronavirus - drug effects
Coronavirus Infections - drug therapy
COVID-19
Drug Repositioning
Humans
Middle East Respiratory Syndrome Coronavirus - drug effects
Niclosamide - pharmacology
Pandemics
Pneumonia, Viral - drug therapy
Review
SARS Virus - drug effects
SARS-CoV-2
Ebola virus
broad antiviral agents
niclosamide
SARS-CoV
coronavirus
MERS-CoV
SARS-CoV-2 (COVID-19)
Zika virus
human adenovirus
flavivirus
Online AccessGet full text

Cover

More Information
Summary:The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article is made available for a limited time sponsored by ACS under the ACS Free to Read License, which permits copying and redistribution of the article for non-commercial scholarly purposes.
ISSN:2373-8227
2373-8227
DOI:10.1021/acsinfecdis.0c00052